Positive Phase III data on the prostate cancer drug Xtandi (enzalutamide) in an expanded indication will take some of the edge off at Pfizer Inc., where the brand's near-term growth prospects fizzled right after the expensive acquisition of Medivation Inc.
Pfizer Poised To PROSPER From Xtandi In Expanded Indication
Pfizer needed good news from the Phase III PROSPER trial testing Xtandi in non-metastatic prostate cancer patients to show investors the Medivation deal was worth the cost. It got what it was hoping for.
